PMID- 26793994
OWN - NLM
STAT- MEDLINE
DCOM- 20160627
LR  - 20220409
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 74
IP  - 3
DP  - 2016 Mar
TI  - Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in 
      patients with metastatic melanoma: A single-institution cohort.
PG  - 455-61.e1
LID - S0190-9622(15)02387-7 [pii]
LID - 10.1016/j.jaad.2015.10.029 [doi]
AB  - BACKGROUND: Anti-programmed cell death (PD)-1 therapy is emerging as the backbone 
      of new standard of care immunotherapy for metastatic melanoma. Immune-related 
      cutaneous events are observed in these patients. OBJECTIVE: We sought to describe 
      cutaneous adverse events observed in patients with metastatic melanoma on 
      anti-PD-1 therapy. METHODS: We reviewed the clinical and histologic information 
      of all patients treated with single-agent anti-PD-1 therapy for metastatic 
      melanoma at Westmead Hospital, Sydney, Australia, from May 2012 to February 2015. 
      RESULTS: Of the 82 patients included in the study, 34 had dermatology 
      assessments. Forty (49%) developed a form of anti-PD-1-associated cutaneous 
      adverse events. In all, 17% developed lichenoid reactions and eczema, and 15% 
      developed vitiligo. An estimated 25% of patients were expected to develop their 
      first lichenoid reactions within 8.3 months, and eczema and vitiligo within 10.3 
      months of therapy. These adverse events tend to appear together in patients on 
      anti-PD-1 therapy. LIMITATIONS: The study was from a single center and clinical 
      information was reviewed retrospectively in patients not referred to dermatology. 
      CONCLUSION: Anti-PD-1 therapy is associated with the development of 
      immune-related cutaneous events. Lichenoid reactions, eczema, and vitiligo are 
      the 3 most prevalent lesions observed in our population. There is a tendency for 
      lichenoid reactions and eczema to occur with vitiligo.
CI  - Copyright (c) 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. 
      All rights reserved.
FAU - Hwang, Shelley Ji Eun
AU  - Hwang SJ
AD  - Department of Dermatology, Westmead Hospital, Sydney, Australia; Sydney Medical 
      School, University of Sydney, Sydney, Australia. Electronic address: 
      shelley.hwang@hotmail.com.
FAU - Carlos, Giuliana
AU  - Carlos G
AD  - Department of Dermatology, Westmead Hospital, Sydney, Australia; Sydney Medical 
      School, University of Sydney, Sydney, Australia.
FAU - Wakade, Deepal
AU  - Wakade D
AD  - Department of Dermatology, Westmead Hospital, Sydney, Australia; Sydney Medical 
      School, University of Sydney, Sydney, Australia.
FAU - Byth, Karen
AU  - Byth K
AD  - Research and Education Network, Westmead Hospital, Sydney, Australia; Sydney 
      Medical School, University of Sydney, Sydney, Australia.
FAU - Kong, Benjamin Y
AU  - Kong BY
AD  - Crown Princess Mary Cancer Center, Westmead Hospital, Sydney, Australia.
FAU - Chou, Shaun
AU  - Chou S
AD  - Tissue Pathology and Diagnostic Oncology, Westmead Hospital, Sydney, Australia.
FAU - Carlino, Matteo S
AU  - Carlino MS
AD  - Crown Princess Mary Cancer Center, Westmead Hospital, Sydney, Australia; Sydney 
      Medical School, University of Sydney, Sydney, Australia; Melanoma Institute 
      Australia, Sydney, Australia.
FAU - Kefford, Richard
AU  - Kefford R
AD  - Crown Princess Mary Cancer Center, Westmead Hospital, Sydney, Australia; Melanoma 
      Institute Australia, Sydney, Australia.
FAU - Fernandez-Penas, Pablo
AU  - Fernandez-Penas P
AD  - Department of Dermatology, Westmead Hospital, Sydney, Australia; Sydney Medical 
      School, University of Sydney, Sydney, Australia.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20160112
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 31YO63LBSN (Nivolumab)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*adverse effects
MH  - Apoptosis/drug effects
MH  - Drug Eruptions/epidemiology/*etiology
MH  - Eczema/*chemically induced
MH  - Female
MH  - Humans
MH  - Lichenoid Eruptions/*chemically induced
MH  - Male
MH  - Melanoma/*drug therapy/*secondary
MH  - Middle Aged
MH  - Nivolumab
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Skin Neoplasms/*drug therapy/*pathology
MH  - Vitiligo/*chemically induced
MH  - Young Adult
OTO - NOTNLM
OT  - anti-programmed cell death-1
OT  - eczema
OT  - immune reaction
OT  - immunotherapy
OT  - lichenoid reaction
OT  - metastatic melanoma
OT  - vitiligo
EDAT- 2016/01/23 06:00
MHDA- 2016/06/28 06:00
CRDT- 2016/01/23 06:00
PHST- 2015/07/24 00:00 [received]
PHST- 2015/10/13 00:00 [revised]
PHST- 2015/10/15 00:00 [accepted]
PHST- 2016/01/23 06:00 [entrez]
PHST- 2016/01/23 06:00 [pubmed]
PHST- 2016/06/28 06:00 [medline]
AID - S0190-9622(15)02387-7 [pii]
AID - 10.1016/j.jaad.2015.10.029 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2016 Mar;74(3):455-61.e1. doi: 10.1016/j.jaad.2015.10.029. 
      Epub 2016 Jan 12.